Cargando…
Recombinant Human Endostatin Endostar Suppresses Angiogenesis and Lymphangiogenesis of Malignant Pleural Effusion in Mice
BACKGROUND: Malignant pleural effusion (MPE) is a common complication of lung cancer. One widely used treatment for MPE is Endostar, a recombined humanized endostatin based treatment. However, the mechanism of this treatment is still unclear. The aim of this study was to investigate the effects of E...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532165/ https://www.ncbi.nlm.nih.gov/pubmed/23285296 http://dx.doi.org/10.1371/journal.pone.0053449 |
_version_ | 1782254263225810944 |
---|---|
author | Ma, Xingqun Yao, Yanwen Yuan, Dongmei Liu, Hongbing Wang, Shouju Zhou, Changsheng Song, Yong |
author_facet | Ma, Xingqun Yao, Yanwen Yuan, Dongmei Liu, Hongbing Wang, Shouju Zhou, Changsheng Song, Yong |
author_sort | Ma, Xingqun |
collection | PubMed |
description | BACKGROUND: Malignant pleural effusion (MPE) is a common complication of lung cancer. One widely used treatment for MPE is Endostar, a recombined humanized endostatin based treatment. However, the mechanism of this treatment is still unclear. The aim of this study was to investigate the effects of Endostar in mice with MPE. METHODS AND MATERIALS: Lewis lung carcinoma (LLC) cell line expressing enhanced green fluorescent protein (EGFP) was injected into pleural cavity to establish MPE mice model. Mice were randomly divided into four groups. High dose of Endostar (30 mg/kg), low dose of Endostar (8 mg/kg), normal saline, or Bevacizumab (5 mg/kg) was respectively injected into pleural cavity three times with 3-day interval in each group. Transverse computed tomography (CT) was performed to observe pleural fluid formation 14 days after LLC cells injection. Mice were anesthetized and sacrificed 3 days after final administration. The volume of pleural effusion n was measured using 1 ml syringe. Micro blood vessel density (MVD), Lymphatic micro vessel density (LMVD), the expression level of vascular endothelial growth factor A (VEGF-A) and VEGF-C were observed by immunohistochemistry (IHC) staining. RESULTS: The volume of pleural effusion as well as the number of pleural tumor foci, MVD and the expression of VEGF-A were significantly reduced in high dose of Endostar treat group. More importantly, LMVD and the expression of VEGF-C were markedly lower in treat group than those in the other three control groups. CONCLUSION: Our work demonstrated that Endostar played an efficient anti-cancer role in MPE through its suppressive effect on angiogenesis and lymphangiogenesis, which provided a certain theoretical basis for the effectiveness of Endostar on the MPE treatment. |
format | Online Article Text |
id | pubmed-3532165 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-35321652013-01-02 Recombinant Human Endostatin Endostar Suppresses Angiogenesis and Lymphangiogenesis of Malignant Pleural Effusion in Mice Ma, Xingqun Yao, Yanwen Yuan, Dongmei Liu, Hongbing Wang, Shouju Zhou, Changsheng Song, Yong PLoS One Research Article BACKGROUND: Malignant pleural effusion (MPE) is a common complication of lung cancer. One widely used treatment for MPE is Endostar, a recombined humanized endostatin based treatment. However, the mechanism of this treatment is still unclear. The aim of this study was to investigate the effects of Endostar in mice with MPE. METHODS AND MATERIALS: Lewis lung carcinoma (LLC) cell line expressing enhanced green fluorescent protein (EGFP) was injected into pleural cavity to establish MPE mice model. Mice were randomly divided into four groups. High dose of Endostar (30 mg/kg), low dose of Endostar (8 mg/kg), normal saline, or Bevacizumab (5 mg/kg) was respectively injected into pleural cavity three times with 3-day interval in each group. Transverse computed tomography (CT) was performed to observe pleural fluid formation 14 days after LLC cells injection. Mice were anesthetized and sacrificed 3 days after final administration. The volume of pleural effusion n was measured using 1 ml syringe. Micro blood vessel density (MVD), Lymphatic micro vessel density (LMVD), the expression level of vascular endothelial growth factor A (VEGF-A) and VEGF-C were observed by immunohistochemistry (IHC) staining. RESULTS: The volume of pleural effusion as well as the number of pleural tumor foci, MVD and the expression of VEGF-A were significantly reduced in high dose of Endostar treat group. More importantly, LMVD and the expression of VEGF-C were markedly lower in treat group than those in the other three control groups. CONCLUSION: Our work demonstrated that Endostar played an efficient anti-cancer role in MPE through its suppressive effect on angiogenesis and lymphangiogenesis, which provided a certain theoretical basis for the effectiveness of Endostar on the MPE treatment. Public Library of Science 2012-12-28 /pmc/articles/PMC3532165/ /pubmed/23285296 http://dx.doi.org/10.1371/journal.pone.0053449 Text en © 2012 Ma et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Ma, Xingqun Yao, Yanwen Yuan, Dongmei Liu, Hongbing Wang, Shouju Zhou, Changsheng Song, Yong Recombinant Human Endostatin Endostar Suppresses Angiogenesis and Lymphangiogenesis of Malignant Pleural Effusion in Mice |
title | Recombinant Human Endostatin Endostar Suppresses Angiogenesis and Lymphangiogenesis of Malignant Pleural Effusion in Mice |
title_full | Recombinant Human Endostatin Endostar Suppresses Angiogenesis and Lymphangiogenesis of Malignant Pleural Effusion in Mice |
title_fullStr | Recombinant Human Endostatin Endostar Suppresses Angiogenesis and Lymphangiogenesis of Malignant Pleural Effusion in Mice |
title_full_unstemmed | Recombinant Human Endostatin Endostar Suppresses Angiogenesis and Lymphangiogenesis of Malignant Pleural Effusion in Mice |
title_short | Recombinant Human Endostatin Endostar Suppresses Angiogenesis and Lymphangiogenesis of Malignant Pleural Effusion in Mice |
title_sort | recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532165/ https://www.ncbi.nlm.nih.gov/pubmed/23285296 http://dx.doi.org/10.1371/journal.pone.0053449 |
work_keys_str_mv | AT maxingqun recombinanthumanendostatinendostarsuppressesangiogenesisandlymphangiogenesisofmalignantpleuraleffusioninmice AT yaoyanwen recombinanthumanendostatinendostarsuppressesangiogenesisandlymphangiogenesisofmalignantpleuraleffusioninmice AT yuandongmei recombinanthumanendostatinendostarsuppressesangiogenesisandlymphangiogenesisofmalignantpleuraleffusioninmice AT liuhongbing recombinanthumanendostatinendostarsuppressesangiogenesisandlymphangiogenesisofmalignantpleuraleffusioninmice AT wangshouju recombinanthumanendostatinendostarsuppressesangiogenesisandlymphangiogenesisofmalignantpleuraleffusioninmice AT zhouchangsheng recombinanthumanendostatinendostarsuppressesangiogenesisandlymphangiogenesisofmalignantpleuraleffusioninmice AT songyong recombinanthumanendostatinendostarsuppressesangiogenesisandlymphangiogenesisofmalignantpleuraleffusioninmice |